These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36270754)

  • 61. Evaluation and Management of Buprenorphine Extended-Release Injection Thrombophlebitis: A Case Report.
    Barrett J; Schapiro R; Casey E; Chertok J
    J Addict Med; 2024 Mar-Apr 01; 18(2):209-211. PubMed ID: 38227854
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment.
    Gray JR; Kehoe LG; Peckham AM; Wakeman SE
    J Addict Med; 2023 Mar-Apr 01; 17(2):227-229. PubMed ID: 36074787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
    Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
    BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
    Rudolph KE; Williams NT; Díaz I; Luo SX; Rotrosen J; Nunes EV
    Am J Epidemiol; 2023 May; 192(5):748-756. PubMed ID: 36549900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial.
    Elarabi HF; Shawky M; Mustafa N; Radwan D; Elarasheed A; Yousif Ali A; Osman M; Kashmar A; Al Kathiri H; Gawad T; Kodera A; Al Jneibi M; Adem A; Lee AJ; Marsden J
    Addiction; 2021 Sep; 116(9):2398-2408. PubMed ID: 33404141
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
    Ruglass LM; Scodes J; Pavlicova M; Campbell ANC; Fitzpatrick S; Barbosa-Leiker C; Burlew K; Greenfield SF; Rotrosen J; Nunes EV
    Drug Alcohol Depend; 2019 Dec; 205():107649. PubMed ID: 31704382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
    Rudolph KE; Williams NT; Goodwin ATS; Shulman M; Fishman M; Díaz I; Luo S; Rotrosen J; Nunes EV
    Drug Alcohol Depend; 2022 Oct; 239():109609. PubMed ID: 36075154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
    Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
    Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
    Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
    Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
    Gordon MS; Mitchell SG; Blue TR; Vocci FJ; Fishman MJ; Murphy SM; Couvillion K; Maher K; Ryan D; Wenzel K; Danner ML; Jarvis DK
    J Subst Abuse Treat; 2021 Sep; 128():108241. PubMed ID: 33339633
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
    Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
    J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.
    Hjelmström P; Banke Nordbeck E; Tiberg F
    Drug Dev Ind Pharm; 2020 Jan; 46(1):1-7. PubMed ID: 31914818
    [No Abstract]   [Full Text] [Related]  

  • 79. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence.
    Lancaster K; Gendera S; Treloar C; Rhodes T; Shahbazi J; Byrne M; Nielsen S; Degenhardt L; Farrell M
    Int J Drug Policy; 2024 Apr; 126():104359. PubMed ID: 38382354
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
    Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
    Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.